MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13054-021-03634-1

Медицинская библиотека · Critical care (London, England) · 2021

Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis.

Ramanathan Kollengode, Shekar Kiran, Ling Ryan Ruiyang, Barbaro Ryan P, Wong Suei Nee, Tan Chuen Seng, Rochwerg Bram, Fernando Shannon M, Takeda Shinhiro, MacLaren Graeme, Fan Eddy, Brodie Daniel

СтатьяМетаанализСистематический обзорПеревод пока не подготовлен

Аннотация

BACKGROUND

There are several reports of extracorporeal membrane oxygenation (ECMO) use in patients with coronavirus disease 2019 (COVID-19) who develop severe acute respiratory distress syndrome (ARDS). We conducted a systematic review and meta-analysis to guide clinical decision-making and future research.

METHODS

We searched MEDLINE, Embase, Cochrane and Scopus databases from 1 December 2019 to 10 January 2021 for observational studies or randomised clinical trials examining ECMO in adults with COVID-19 ARDS. We performed random-effects meta-analyses and meta-regression, assessed risk of bias using the Joanna Briggs Institute checklist and rated the certainty of evidence using the GRADE approach. Survival outcomes were presented as pooled proportions while continuous outcomes were presented as pooled means, both with corresponding 95% confidence intervals [CIs]. The primary outcome was in-hospital mortality. Secondary outcomes were duration of ECMO therapy and mechanical ventilation, weaning rate from ECMO and complications during ECMO.

RESULTS

We included twenty-two observational studies with 1896 patients in the meta-analysis. Venovenous ECMO was the predominant mode used (98.6%). The pooled in-hospital mortality in COVID-19 patients (22 studies, 1896 patients) supported with ECMO was 37.1% (95% CI 32.3-42.0%, high certainty). Pooled mortality in the venovenous ECMO group was 35.7% (95% CI 30.7-40.7%, high certainty). Meta-regression found that age and ECMO duration were associated with increased mortality. Duration of ECMO support (18 studies, 1844 patients) was 15.1 days (95% CI 13.4-18.7). Weaning from ECMO (17 studies, 1412 patients) was accomplished in 67.6% (95% CI 50.5-82.7%) of patients. There were a total of 1583 ECMO complications reported (18 studies, 1721 patients) and renal complications were the most common.

CONCLUSION

The majority of patients received venovenous ECMO support for COVID-19-related ARDS. In-hospital mortality in patients receiving ECMO support for COVID-19 was 37.1% during the first year of the pandemic, similar to those with non-COVID-19-related ARDS. Increasing age was a risk factor for death. Venovenous ECMO appears to be an effective intervention in selected patients with COVID-19-related ARDS. PROSPERO CRD42020192627.

Для цитирования: Ramanathan Kollengode, Shekar Kiran, Ling Ryan Ruiyang, Barbaro Ryan P, Wong Suei Nee, Tan Chuen Seng, Rochwerg Bram, Fernando Shannon M, Takeda Shinhiro, MacLaren Graeme, Fan Eddy, Brodie Daniel. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis.. Critical care (London, England). 2021. DOI: 10.1186/s13054-021-03634-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.